Biogen (BIIB) EPS Diluted: History & Chart

Biogen Inc. (BIIB)BIIBBiogen Inc.

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

BIIB EPS Diluted Metrics

EPS DILUTED

8.83

EPS DILUTED AVG TTM

10.01

EPS DILUTED AVG 3Y

12.21

EPS DILUTED AVG 5Y

14.01

EPS DILUTED AVG 10Y

16.48

EPS DILUTED AVG 15Y

13.51

EPS DILUTED AVG 20Y

10.73

CURRENT VS TTM AVG

-11.79%

CURRENT VS 3Y AVG

-27.71%

CURRENT VS 5Y AVG

-36.97%

CURRENT VS 10Y AVG

-46.41%

CURRENT VS 15Y AVG

-34.64%

CURRENT VS 20Y AVG

-17.68%

EPS Diluted FAQ

What is the EPS diluted for Biogen Inc. (BIIB)?

The EPS diluted for BIIB stock is 8.83.

Is Biogen Inc.'s EPS diluted high or low?

The EPS diluted of 8.83 is 37% below its 5-year average of 14.01, near the low end of its 5-year range (7.97–24.80).

What is the TTM average EPS diluted for Biogen Inc. (BIIB)?

The TTM average EPS diluted for BIIB stock is 10.01.

What is the 3Y average EPS diluted for Biogen Inc. (BIIB)?

The 3Y average EPS diluted for BIIB stock is 12.21.

What is the 5Y average EPS diluted for Biogen Inc. (BIIB)?

The 5Y average EPS diluted for BIIB stock is 14.01.

What is the 10Y average EPS diluted for Biogen Inc. (BIIB)?

The 10Y average EPS diluted for BIIB stock is 16.48.

What is the 15Y average EPS diluted for Biogen Inc. (BIIB)?

The 15Y average EPS diluted for BIIB stock is 13.51.

What is the 20Y average EPS diluted for Biogen Inc. (BIIB)?

The 20Y average EPS diluted for BIIB stock is 10.73.

DATE	EPS DILUTED
2025-12-31	8.83
2024-12-31	11.19
2023-12-31	7.97
2022-12-31	20.87
2021-12-31	10.40
2020-12-31	24.80
2019-12-31	31.42
2018-12-31	21.58
2017-12-31	11.92
2016-12-31	16.93
2015-12-31	15.34
2014-12-31	12.37
2013-12-31	7.81
2012-12-31	5.76
2011-12-31	5.04
2010-12-31	3.94
2009-12-31	3.35
2008-12-31	2.65
2007-12-31	1.99
2006-12-31	0.63
2005-12-31	0.47
2004-12-31	0.07
2003-12-31	-2.62
2002-12-31	0.50
2001-12-31	0.68
2000-12-31	0.72
1999-12-31	0.47
1998-12-31	0.15
1997-12-31	0.10
1996-12-31	0.04

DATE

EPS DILUTED

2025-12-31

8.83

2024-12-31

11.19

2023-12-31

7.97

2022-12-31

20.87

2021-12-31

10.40

2020-12-31

24.80

2019-12-31

31.42

2018-12-31

21.58

2017-12-31

11.92

2016-12-31

16.93

2015-12-31

15.34

2014-12-31

12.37

2013-12-31

7.81

2012-12-31

5.76

2011-12-31

5.04

2010-12-31

3.94

2009-12-31

3.35

2008-12-31

2.65

2007-12-31

1.99

2006-12-31

0.63

2005-12-31

0.47

2004-12-31

0.07

2003-12-31

-2.62

2002-12-31

0.50

2001-12-31

0.68

2000-12-31

0.72

1999-12-31

0.47

1998-12-31

0.15

1997-12-31

0.10

1996-12-31

0.04

EPS Diluted: 8.83

BIIB EPS Diluted

BIIB Average EPS Diluted Chart

BIIB Current vs Average EPS Diluted Chart

BIIB EPS Diluted Metrics

EPS Diluted Formula & Definition

EPS Diluted FAQ

BIIB EPS Diluted History

Related Metrics